Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
PR96169
NEW YORK, May 25, 2022 /PRNewswire=KYODO JBN/ --
-Insilico's candidate demonstrated a favorable profile with good in vivo
efficacy at low doses, efficient synthesis, and no need for co-administration
with Ritonavir.
-The candidate is intended to be used for the treatment of SARS-CoV-2 and its
variants, along with other coronaviruses.
-Insilico's candidate has a novel structure that can be synthesized
efficiently, designed by its propriety AI-driven small molecule generation
platform, Chemistry42.
Insilico Medicine, a clinical-stage end-to-end artificial intelligence
(AI)-driven drug discovery company, today announced its nomination of a novel
preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment
of COVID-19.
Insilico's PCC is an orally available 3CL protease inhibitor with a novel
structure generated using Insilico's AI platform. The compound can be
efficiently prepared with a two-step synthesis from commercial starting
materials. In preclinical studies, it demonstrated a favorable profile with
good in vivo efficacy at low doses and its observed efficacy is independent of
co-administration with CYP3A4/Pgp inhibitor (e.g. Ritonavir). It also showed
broad-spectrum antiviral activities, not only for SARS-CoV-2 and its variants,
but also for other types of coronaviruses that cause diseases including severe
acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).
"This molecule designed by AI has distinct pharmacophores from existing 3CL
protease inhibitors and binds to the target protein in a unique, irreversible,
covalent binding mode as demonstrated by a co-crystal structure," said Feng
Ren, Ph.D., Chief Scientific Officer of Insilico Medicine. "We are committed to
progress the molecule as fast as possible into clinical trials evaluating its
usage in COVID-19 treatment."
Insilico initially trained its end-to-end AI platform to combat the pandemic
early in the outbreak based on knowledge of the virus' structure and properties
developed from the SARS outbreak in 2003. Empowered by its AI platform, the
company narrowed and identified the 3CL target in early 2020 and then published
its first set of novel compound structures designed using its small molecule
generation platform Chemistry42 in February 2020.
"The COVID-19 pandemic brought global attention to the pressing need for rapid
drug development," said Alex Zhavoronkov, Ph.D., Founder and CEO of Insilico
Medicine. "We made an executive decision to start our COVID-19 program early.
We were mobilized along with the rest of the scientific community and were able
to demonstrate how powerful AI tools can be in the fight against the disease."
The epidemic caused by the Novel Coronavirus has had a significant impact on
human health and economic development and has brought severe challenges to
global public health security. Insilico's R&D team has initiated
investigational new drug (IND)-enabling studies for the PCC to accelerate its
progression to a clinical asset.
Since 2021, Insilico has nominated 7 preclinical candidates discovered and
designed using its AI platform in a variety of disease areas, including
fibrosis, inflammation, and cancer. It also successfully completed a Phase 0
microdose trial and entered a Phase I clinical trial with its first internally
developed program for fibrosis.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence
(AI)-driven drug discovery company, is connecting biology, chemistry, and
clinical trials analysis using next-generation AI systems. The company has
developed AI platforms that utilize deep generative models, reinforcement
learning, transformers, and other modern machine learning techniques to
discover novel targets and to design novel molecular structures with desired
properties. Insilico Medicine is delivering breakthrough solutions to discover
and develop innovative drugs for cancer, fibrosis, immunity, central nervous
system (CNS) diseases and aging-related diseases.
For more information, visit www.insilico.com .
For media inquiries, please contact media@insilicomedicine.com.
Source: Insilico Medicine
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=421956
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。